New approaches in the management of choroidal neovascular membrane in age-related macular degeneration

Indian Journal of Ophthalmology

Volumn 48, Issue 4, 2000, Pages 263-278

  Verma, Lalit ^a   Das, Taraprasad ^b   Binder, Susanne ^c   Heriot, Wilson J ^e   Kirchhof, Bernd ^f   Venkatesh, Pradeep ^a   Krebs, Ilse ^c   Stolba, Ulrike ^c   Jahn, Christian ^c   Feichtinger, Hans ^g   Kellner, Lukas ^c   Krugluger, H ^g   Pawelka, I ^d   Frohner, Ursula ^c   Kruger, Andreas ^g   Li, Wenhua ^b   Tewari, Hem K ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^b L V PRASAD EYE INSTITUTE   (India)

^c Rudolf Foundation Hospital   (Austria)

^d University Children's   (Austria)

^e UNIVERSITY OF MELBOURNE   (Australia)

^f RWTH AACHEN UNIVERSITY   (Germany)

^g LV Prasad Marg ^*

Author keywords

Age related macular degeneration; Laser photocoagulation; Photodynamic therapy; Radiotherapy; Submacular haemorrhage; Subretinal surgery; tPA

Indexed keywords

BLINDNESS; HUMAN; INCIDENCE; LASER COAGULATION; PHOTOCHEMOTHERAPY; PIGMENT EPITHELIUM; PREVALENCE; PROGNOSIS; RADIOTHERAPY; RETINA MACULA DEGENERATION; REVIEW; SUBRETINAL NEOVASCULARIZATION; TRANSPLANTATION; VISUAL ACUITY;

BLINDNESS; CHOROIDAL NEOVASCULARIZATION; HUMANS; INCIDENCE; LASER COAGULATION; MACULAR DEGENERATION; PHOTOCHEMOTHERAPY; PIGMENT EPITHELIUM OF EYE; PREVALENCE; PROGNOSIS; RADIOTHERAPY; VISUAL ACUITY;

EID: 0034574727     PISSN: 03014738     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (105)

1. Klein R, Klein BEK, Linton KLP. Prevalence of age-related maculopathy: The Beaver Dam Eye Study. Ophthalmology 1992; 99: 933-43.
2. Mitchell P, Smith W, Altebo K, Wang JJ. Prevalence of age-related maculopathy in Australia: The Blue Mountain Eye Study. Ophthalmology 1995; 102: 1450-60.
3. Vingerling JR, Diclemans I, Hofman A, Grobbee DE, Hijmering M, Kramer CF. The prevalence of age-related maculopathy in the Rotterdam Study. Ophthalmology 1995; 102: 205-210.
4. Narendran V, Tulsiraj RD, Kim R, Selvaraj, Katz J, Robin AR, et al. The prevalence of age-related maculopathy in south India. Invest Ophthalmol Vis Sci (Abstract) 2000;41:S119
5. Vingerling JR, Laverce K, Hofman A, dejong PT. Epidemiology of age-related maculopathy. Epidemiolol Rev. 1995; 17: 347-60.
6. Chumbley LC. Impressions of eye diseases among Rhodesian blacks in Mashonaland. S Afr Med J 1977; 52: 316-18
7. Gregor Z, Joffe L. Senile macular changes in the black Africans. Br J Ophthalmol 1978; 62: 547-50.
8. Schachat AP, Hyman L, Leske MC, Connell AM, W Sy. Features of age-related macular degeneration in a black population: the Barbados Eye Study Group. Arch Ophthalmol 1995; 113: 728-35.
9. Jampol LM, Tielsch J. Race, macular degeneration, and macular phtocoagulation study. Arch Ophthalmol 1992; 110: 1699-1700.
10. Gren WR, Enger C. Age-related macular degeneration histological studies: The 1992 Lorenz E Zimmerman lecture. Ophthalmology 1993; 100: 1519-35.
11. Bressler NM, Silva JC, Bressler SB, Fine SL, Green WR. Clinicopathologic correlation of drusen and retinal pigment epithelial abnormalities in age-related macular degeneration. Retina 1994;14:130-42.
12. Smiddy WE, Fine SL. Prognosis of patients with bilateral macular drusen. Ophthalmology 1984; 91: 271-77
13. Holz FG, Wolfensberger TJ, Piguet B, Jendroska MG, Wells JA, Minasslan DC et al. Bilateral macular drusen in Age-related macular degeneration: Prognosis and risk factors. Ophthalmology 1994; 101: 1522-28.
14. Macular Photocoagulation Study Group. Subfoveal neovascular lesions in age-related macular degeneration: Guidelines for evaluation and treatment in the Macular Photocogulation study. Arch Ophthalmol 1991; 109: 1242-57.
15. Green WR, Harlan JB Jr. Histological features. In Berger JW, Fine SL, Maguire MG, Editors, Age-related Macular Degeneration St. Louis: C V Mosby.1999; pp 99.
16. Yannuzzi LA, Slakter JS, Sorenson JA, Guyer DA, Orlock DA. Digital indocyanine green videoangiography and choroidal neovascularization. Retina 1992; 12: 191-223
17. Kwun RC, Guyer DR. Indocyanine green angiography. In Berger JW, Fine SL, Maguire MG, Editors, Age-related Macular Degeneration St. Louis: Mosby.1999; pp 239.
18. Guyer DR, Yannuzzi LA. Ocult choroidal neovascularization. In Yannuzzi LA, Flower RW, Slakter JS. Editors, Indocyanine Green Angiography St Louis: Mosby, 1997; pp 172.
19. Fine SL. The Macular Photocoagulation Study (Editorial). Arch Ophthalmol 1980; 98: 832.
20. Holekamp NM, Thomas MA. The submacular surgery trials. In Kertes PJ, Conway MD, Editors, Clinical Trials in Ophthalmology. A Summary and Practice Guide Philadelphia. Lippincott Williams & Wilkins, 2000; pp 185-94.
21. Bloom SM, Brucker AJ. Choroidal neovascuralization. In Laser Surgery of Posterior Segment. Philadelphia. Lippincott-Raven. pp. 173-270.
22. Yannuzzi LA. Krypton laser photocoagulation for subretinal neovascularization. Retina 1982; 2: 29-46.
23. Macular Photocoagulation Study Group. Argon laser photocoagulation in senile macular degeneraton : Results of a randomized clinical trial. Arch Ophthalmol 1982; 100: 912-18.
24. Chamerlin JA, Bressler NM, Breser SB, Elmann MJ, Murphy RP, Flood TP et al. The use of fundus photographs and fluorescein angiograms in the identification and treatment of choroidal neovascularization in the macular photocoagulation study. Ophthalmology 1989; 96: 1526-34
25. Moisseiev J, Alhalel A, Masuri R, Treister G. The impact of the macular photocoagulation study result on the treatment of exudative age-related macular degeneration. Arch Ophthalmol 1995; 113; 185-93.
26. Macular Photocoagulation Study Group. Argon laser photocoagulation for neovascular maculopathy: five year result from randomized clinical trial. Arch Ophthalmol 1991; 109; 1109-14.
27. Macular Photocoagulation Study Group. Laser photocoagulation for juxtafoveal choroidal neovascularization: five year result from randomized clinical trial. Arch Ophthalmol 1994; 112: 500-09.
28. Macular Photocoagulation Study Group. Peristent and recurrent neovascularization after laser photocoagulation for subfoveal choroidal neovascularization of age-related macular degeneration. Arch Ophthalmol 1994; 112: 489-99.
29. de Juan E jr, Machemer R. Vitreous surgery for hemorrhagic and fibrous complications of age-related macular degeneration. Am J Ophthalmol 1988; 105: 25-29.
30. Saxena S, Thomas MA, Melberg NS. Submacular surgery. Indian J Ophthalmol 1997; 45: 77-92.
31. Melberg NS, Thomas MA, Burgess DB. The surgical removal of subfoveal choroidal neovasscularization : in growth site as a predictor of visual outcome. Retina 1996; 16: 190-95.
32. Arlett CF, Harcourt SA. Survey of radiosensitivity in a variety of human cell strains. Cancer Res 1980; 40: 926-32.
33. Amoakg WM, Frew L, Mahon GJ, Gardiner TA, Archer DB. Early ultrastructural changes after low dose X-irradiation in the retina of the rat. Eye 1989; 3: 638-46.
34. Archer DB, Amoaku WM, Gardiner TA. Radiation retinopathy-clinical, histological, ultrastructural and experimental correlation. Eye 1991; 5:239-51.
35. Irvine AR, Wood IS. Radiation retinopathy as an experimental model for ischemic proliferative retinopathy and rubeosis iridis. Am J Ophthalmol 1987; 103: 790-97
36. Sherr DL, Finger PT. Radiation therapy for age-related macular degeneration. Semin Ophthalmol 1997;12: 26-33.
37. Chakrabarthy U, Houston RF, Archer DB. Treatment of age-related subfoveal neovascular membrane by tele therapy: A pilot study. Br J Ophthalmol. 1993; 77: 265-73.
38. Donati G, Soubrane D, Quaranta M, Coscas G, Soubranes G. Radiotherapy for isolated occult subfoveal neovascularisation in age-related macular degeneration: a pilot study. Br J Ophthalmol 1999; 83: 646-651.
39. Stalmans P, Leys A, van Limbergen E. External beam radiotherapy (20 gy, 2 gy fractions) fails to control the growth of choroid neovascularization in age-related macular degeneration: a review of 111 cases. Retina 1997; 17: 481-92.
40. Spaide RF, Guyer DR, McCormick B, Yannuzzi LA, Burke K, Mendeljohn M, et al. External beam radiation therapy for choroidal neovascularization. Ophthalmology 1998; 105: 24-30.
41. Tholen AM, Meisher A, Bernasconi PP, Messmer EP, Radiotherapy for choroidal neovascularization in age-related macular degeneration. A pilot study using low-versus high dose proton beam radiation in age-related related macular degeneration. Ophthalmology. 1998; 95: 691-98.
42. Bergink G-J, Hoyng CB, Vander Maazen RW, Vingerling JR, vanDaal WA, Deutman AF, A randomized controlled clinical trial on the efficacy of radiation therapy in the control of subfoveal choroidal neovascularization in age-related macular degeneration: Radiation versus observation. Graefes Arch Clin Exp Ophthalmol 1998; 236: 321-325.
43. Holz FR, Eugenhart-Cabillic R, Unnebrink KK, Bellmann C, Debus J, Pritsch M, et al. A prospective, randomized, double-blind trial on radiation therapy for neovascular age-related macular degeneration (RAD study). Ophhtalmology 1999; 106: 2239-2247.
44. Hussain D, Gragoudas ES, Miller J. Photodynamic therapy. In Berger JQ, Fine SL. Maguire MG, Editors Age-related Macular Degeneration St. Louis, Mosby. 1999; pp 297-307.
45. Schimdt-Erfurth U, Miller JW, Sickenberg M et al. Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration: results of retreatment in a phase 1 and 2 study. Arch Ophthalmol 1999; 117: 1177-1187.
46. Treatment of Age-related Macular Degeneration with Photodynamic Therapy (TAP) Study Group: Photodynamic therapy of subfoveal choroidal neovascularizatio in age-related macular degeneration with Verteporfin. One-year results of 2 randomized clinical trials-TAP report 1. Arch Ophthalmol 1999; 117; 1329-45.
47. Thomas EL Rosen RP, Murphy R, Puliafito C, Seyedsade P, Jensson P, et al. Purlytin-photodynamic therapy produces closure of subfoveal choroidal neovascularization in humans. Invest Ophthalmol Vis Sci (Abstract) 1998; 39: s 242
48. Thomas EL, Rosen R, Murphy RP, Jonsson P. Visual acuity stabilizes after a single treatment with SnET2-photodynamic therapy in patients with subfoveal choroidal neovasciularization. Invest Ophthalmol Vis Sci (Abstract) 1999; 40; s 401.
49. Regillo CD. Update on photodynamic therapy. Curr Opin Opthalmol 2000;11:166-70.
50. Machemer R, Steinhorst UH. Retinal separation, retinotomy, and macular relocation: II. A surgical approach for age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 1993; 231: 635-41.
51. Wolf S, Lapas A, Weinberger A, Krchof B. Erste Erfahrungen mit makularer translocation zur behnadlung subfovealer choroidaler neovascularisationen. Klin Monatsble Augenheilkd 1997;210:5.
52. Wolf S, Lappas A, Weinberger AW, Kirchhof B. Macular translocation for surgical management of subfoveal choroidal neovascularizations in patients with AMD: First results. Graefe's Arch Clin Exp Ophthalmol 1999; 237: 51-57.
53. Eckardt C, Eckardt U, Conrad HG. Macular rotation with and without counter-rotation of the globe in patients with age-related macular degeneration. Grefe's Arch Clin Exp Ophthalmol 1999;237:313-25.
54. Nimoniya Y, Lewis JM, Hasegawa T, Tono Y. Retinotomy and foveal translocation for surgical management of subfoveal choroidal neovascular membranes. Am J Ophthalmol 1996;122:613-21.
55. de Juan E Jr, Lowenstein AL, Bressler NM, Alexander J. Translocation of the retina for management of subfoveal choroidal neovascularization. II: A preliminary report in humans. Am J Ophthalmol 1998;125:535-46
56. Lewis H, Kaiser PK, Lewis S, Estafanous M. Macular translocation for subfoveal choroidal neovascularization in age-related macular degeneration: A prospective study. Am J Ophthalmol 1999;128:135-46.
57. Fujikado T, Ohji M, Hayashi A. Anatomic and functional recovery of the fovea after foveal translocation surgery without large retinotomy and simultaneous excision of neovascular membrane. Am J Ophthalmol 1998; 126:839-42.
58. Fricke J, Neugebauer A, Kirsch A, Bartz-Schmidt KU, Russmann W. Muskelchirurgische gegenrotation des bulbus bei makulatranslokation. Ophthalmoge (Abstract) 1999;96:S3.
59. Faude F, Wiedemann P, Reichenbach A. A "detachment infusion" for macular translocation surgery. Retina 1999;19:173-74.
60. Phillips SJ, Fujii GY, Peiramici DJ, Kent D, de Juan E Jr. Persistent and recurrent neovacularization after successful macular translocation for subfoveal choroidal noevacscularization of age-related macular degeneration. Invest Ophthalmol Vis Sci (Abstract) 2000; 41:s541.
61. Turner JE. Blair JR: Newborn rat retinal cells transplanted into a retinal lesion site in adult host eyes. Brain Res. 1986, 391: 91-104
62. del Cerro M. Notter MF.del Cherrc C. Wigand SJ. Grover DA Lazar E: Intra retinal transplantation for rod-cell replacement in light damaged retinas. J Neural Transplant 1989, 1:1-10
63. Das T, del Cerro M, Jalali S; Rao VS, Gullapalli VK, Little C, et al. The transplantation of human fetal neuroretinal cells in advanced retinitis pigmentosa: results of a longterm safety study. Exp Neurol 1999; 157: 58-68.
64. Silvermann MS. Hughes SE: Transplantation of phtoreceptors to light damaged retinas. Invest Ophthalmol Vis Sci 1989, 30:1684-90.
65. Kaplan HJ. Tetzel TH. Berger AS. Wolf ML. Del-Priore L: Human photoreceptor transplantation in retinitis pigmentos. A safety study. Arch Ophthalmol 1997;115:1168-72.
66. Ghosh F. Bruun A. Ehinger B: Graft host connections in long full thickness embryonic retinal transplants. Invest Ophthalmol Vis Sci 1999;40:126-32.
67. Algvere PV, Berglin L, Guras P, Sheng Y, Kopp ED. Human fetal RPR transplants in Age-related macular degeneration (ARMD) Grafe's Arch Clin Exp Ophthalmol, 1997;235:149-58.
68. Gelanee M. Breipohl W. Wiedemann P. Naib - Majani W. Heimann K. First experimental iris pigment epithelial transplantation in subretinal space of RCS rat, Invest. Ophthalmol Vis Sci (Abstract) 1993;34:s 107.
69. Gelance M, Meneses P, Rosenfeld MR, Duvoisin RM, Coleman D. Long term results of autologous transplantation of iris pigment epithelial cells into the subretinal space: Invest Ophthalmol Vis Sci 1997;38:334-39.
70. Lai WW, Rezaei KA, Farrokh - Siar L, Pearlmann J, Shu J, Patel SC, et al. A new method of culturing and transferring iris pigment epithelium, Invest Ophthalmol Vis Sc 1997;38:335-41.
71. Mashhour B. Renard G. Iris pigment epithelium autotransplantation in exudative ARMD. Invest Ophthalmol Vis Sci 1997;38:657.
72. Thurmann G, Bartz-Schmidt KU, Heimann K, Schraemayer U. Phagocytosis of rod outer segments by human iris pigment epithelial cells in vitro. Graefes Arch Chin Exp Ophthalmol. 1998;236:753-57.
73. Bisntis F. Fragona I. Mancini A. Dalla Pozza G. Bisantis C. Is phagocytosis in iris pigment epithelium (IPE) cultures by human iridectomies a self-limited and dose dependant mechanism? Invest Ophthalmol Vis Sci 1997; 38:330.
74. Dintelmann TS. Heimann K. Kayatz P. Schraemeyer U. Comparative study of ROS degradation by IPE and RPE cells in Vitro: Graefes Arch clin Exp 1999;237, 830-39.
75. Thumann G, Aisenbreg S, Schraermeyer U, Lafant B, Esser P, Walter P, Bartz-Schmidt KU. Transplantation of autologous iris pigment epithelium after removal of choroidal neovascular membranes. Arch Ophthalml 2000;118:1350-55.
76. Tamai M. Abe T. Tomita H. Yoshida M. Kano T. Sato M. Autologous iris pigment transplantation in Age-related macular Degeneration. In Das T., Editor RETINA. Current Practice and Future Trends. Hyderabad Paras Publishing, 1999; 151-61.
77. Panda-Joans S. Jonas JB. Jacobczyk-Zmija M. Retinal pigment epithelial cell count, distribution, and correlations in normal human eyes. Am J Ophthalmol, 1996;121:181-89.
78. Solbach U. Keilhauer C. Knabben H. Wolf S. Imaging of retinal autofluorescence in patients with age-related macular degeneration. Retina 1997;17: 385-89.
79. V on. Ruckmann A. Fitzke FW. Bird AC: Distribution of pigment epithelium autofluorescence in retinal disease state recorded in vivo and its change over time. Gaefes Arch Clin Exp Ophthalmol, 1999; 237:1-9.
80. Avery RL, Fekrat S, Hawkins BS, Bressler NM. Natural history of subfoveal hemorrhage in age-related macular degeneration. Retina 1996; 16:183-89.
81. Scupola A, Coscas G, Soubrane G, Balestrazzi E. Natural history of macular subretinal hemorrhage in age-related macular degeneration. Ophthalmoligica 1999; 213: 97-102.
82. Berrocal MH, Lewis ML, Flynn HW Jr. Variations in the clinical course of submacular hemorrhage. Am J Ophthalmol 1996; 122: 486-93.
83. Chen WL, Liu JH, Lee FL Natural course of submacular hemorrhage. Chung Hua I Hsueh Tsa Chih (Taipei) 1999; 62: 268-77.
84. Bennett SR, Folk JC, Blodi FC, Klugman M. Factors prognostic of visual outcome in patients with subretinal hemorrhage. Am J Ophthalmol 1990;109: 33-7.
85. Lim JI. Subretinal hemorrhage. In: Sternberg P and Lim JI. Editors Macular Disease. Int Ophthalmol Clin 1995; 35: 95-104.
86. Peyman GA, Nelson NC Jr, Alturki W, Blinder Kj, Paris CL, Desai VR et al. Tissue plasmingoen activating factor assisted removal of subretinal hemorrhage. Ophthalmic Surg 1991; 22:575-82.
87. Johnson MW; Olsen KR; Hernandez E. Tissue plasminogen activator thrombolysis during surgical evacuation of experimental subretinal hemorrhage. Ophthalmology 1992; 99: 515-21.
88. Hess L, Meitinger D, Schmidt J. Little effect of tissue plasminogen activator in subretinal surgery for acute hemorrhage in age-related macular degeneration. Ger J Ophthalmol 1996; 5: 489-83.
89. Claes C, Zivojnovic R. Efficacy of tissue plasminogen activator (t-PA) in subretinal hemorrhage removal. Bull Sco Belge Ophthalmol 1996;261:115-18.
90. Ibanez HE, Williams DF, Thomas MA, Ruby AF, Meredith TA, Bonink I, et al. Surgical management of submacular hemorrhage. A series of 47 consecutive cases. Arch Ophthalmol 1995;113:62-69.
91. Hochman MA, Seery CM, Zarbin MA. Pathophysiology and management of subretinal hemorrhage. Surv Ophthalmol 1997; 42: 195-213.
92. Kimura AE, Reddy CV, Folk JC, Farmer SG. Removal of subretinal haemorrhage facilitated by preoperative intravitreal tissue plasminogen activator [letter]. Retina 1994; 14:83-4.
93. Coll GE, Sparrow JR, Marinovic A; Chang S. Effect of intravitreal injection of tissue plasminogen activator on experimental subretinal hemorrhage. Retina 1995; 15:319-26.
94. Hesse L, Schmidt J, Kroll P. Management of acute submacular haemorrhage using recombinant tissue plasminogen activator and gas. Graefes Arch Clin Exp Ophthalmol 1999; 237:273-77.
95. Hassan AS, Johnson MW, Schneiderman TE, Regillo CD, Tornambe PE, Poliner LS, et al. Management of submacular haemorrhage with intravitreous tissue plasminogen activator injection and pneumatic displacement. Ophthalmology 1999;106:1900-6; (Discussion 1906-7).
96. Kokame GT. Vitreous hemorrhage after intravitreal tissue plasminogen activaor (t-PA) and pneumatic displacement of submacular hemorrhage. Am J Ophthalmol 2000; 129: 546-47.
97. Krepler K, Kruger A, Tittl M, Stur M, Wedrich A. Intravitreal injection of tissue plasminogen activator and gas in subretintal hemorrhage caused by age-related macular degeneration. Retina 2000;20:251-56.
98. Framme C, Toukhy HE, Sachs HG, Spiegel D, Roider J, Gabel VP, et al. Clinical results of intravitreal administration of tissue-type plasminogen activator (tPA) and gas for removal of subretinal hemorrhage in senile macular degeneration. Klin Monatsbl Augenheilkd 2000; 216: 33-39.
99. Buhl M, Scheider A, Schonfeld CL, Kampik A. Intravitreal rt-PA and gas introduction in submacular haemorrhage. Ophthalmolge 1999;96:792-96.
100. Hesse L, Kroll P. Successful treatment of acute subretinal hemorrhage in age-related macular degeneration by combined intravitreal injection of recombinant tissue plasminogen activator and gas. Adv Ther 1997; 14: 275-80.
101. Ohji M, Saito Y, Hayashi A, Lewis JM, Tano Y. Pneumatic displacement of subretinal hemorrhage without tissue plasminogen activator. Arch Ophthalmol 1998; 116:1326-32.
102. Daneshvar H, Kertes PJ, Leonard BC, Peyman GA. Management of submacular hemorrhage with intravitreal sulfur hexafluoride: a pilot study. Can J Ophthalmol 1999; 34: 385-88.
103. Tornambe PE. Pneumatic retinopexy: current status and future directions. Int Ophthalmol Clin. 1992; 32: 61-80.
104. Benner JD, Morse LS, Toth CA, Landers MB III, Hjelmeland LM. Evaluation of a commercial recombinant tissue-type plasminogen activator preparation in the subretinal space of the cat. Arch Ophthalmol 1991;109:1731-36.
105. Kamei M, Misono K, Lewis H. A study of the ability of tissue plasminogen activator to diffuse into the subretinal space after intravitreal injection in rabbits. Am J Ophthalmol 1999;128: 739-46.